Hancock Jaffe to Present VenoValve Case Management Report at Expert Venous Management Conference on June 7, 2019

May 28, 2019 8:31 AM

Initial Patient Data to be Released on June 7th for First-In-Human VenoValve Study IRVINE, CA / ACCESSWIRE / May 28, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, will report initial data on the first five patients that received VenoValves as part of the first-in-human study in Bogota, Colombia, and will present a case management report at the Expert Venous...

Read more

Hancock Jaffe Announces Retirement of Board Chairman Yury Zhivilo

May 24, 2019 8:31 AM

IRVINE, CA / ACCESSWIRE / May 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has announced that its Chairman, Yury Zhivilo, is retiring from its board of directors. Mr. Zhivilo first became interested in Hancock Jaffe when at age 41, he was in need of a heart valve replacement surgery. Following that experience he made a significant investment in Hancock...

Read more

Pieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the American Thoracic Society (ATS) 2019 International Conference

May 22, 2019 2:30 PM

BOSTON, MA / ACCESSWIRE / May 22, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the presentation of placebo-controlled single ascending dose Phase 1a data for AZD1402/PRS-060, an inhaled IL-4Rα antagonist being developed in collaboration with...

Read more

Hancock Jaffe Expands CoreoGraft Feasibility Study

May 21, 2019 8:31 AM

Longer-Term Phase of the Trial Started with Additional Test Subjects IRVINE, CA / ACCESSWIRE / May 21, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has announced the expansion of its feasibility study for the CoreoGraft. The pre-clinical study has been expanded to include additional animals and a longer term. One group of new test subjects will be...

Read more

ORYZON Receives $1.5 Million Grant from Alzheimer's Drug Discovery Foundation (ADDF)

May 20, 2019 9:50 AM

Proceeds to help fund ETHERAL-US Phase IIa examing vafidemstat in Alzheimer's disease ADDF stake in the company represents 0.94 % of the common stock MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / May 20, 2019 / Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the Board of...

Read more

Red from Alcohol? SRQ Laboratories Releases the Results of the Largest Ever Asian Flush Survey

May 17, 2019 10:40 AM

The Team from London-Based SRQ Laboratories Surveyed More than 9,000 People of Asian Descent to Learn More About what is Commonly Called "Asian Glow" and How to Prevent It LONDON, UK / ACCESSWIRE / May 17, 2019 / The founders of SRQ Laboratories, a London-based company that focuses on researching and developing products that help with the alcohol flush reaction, are pleased to announce the they have just released the results of the world's...

Read more

Dyadic to Present at the 20th Annual B. Riley FBR Investor Conference and Upcoming Industry Events

May 17, 2019 8:15 AM

JUPITER, FL / ACCESSWIRE / May 17, 2019 / Dyadic International, Inc. (the ''Company'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive...

Read more

Pressure BioSciences, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

May 16, 2019 11:00 AM

Q1 Revenue from Newly Created BioPharma and UST Contract Services Significantly Exceeds Services Revenue for All Quarters of 2018 Combined Investor Conference Call Scheduled for Thursday, May 16, 2019 at 4:30 PM EST SOUTH EASTON, MA / ACCESSWIRE / May 16, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform...

Read more

Pressure BioSciences, Inc. to Discuss First Quarter 2019 Financial Results and Provide Business Update

May 15, 2019 8:10 PM

Conference Call Scheduled for Thursday, May 16th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / May 15, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2019 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link...

Read more

Kerastem Licenses China and ASEAN Hair Growth Markets to MyungMoon Bio; Company Expands Upon Existing Partnership in South Korea

May 14, 2019 8:30 AM

SOLANA BEACH, CA and SEOUL, SOUTH KOREA / ACCESSWIRE / May 14, 2019 / Kerastem, the leader in the development and commercialization of regenerative medicine-based approaches to hair growth, and MyungMoon Bio Co. Ltd, a leading healthcare company bringing innovative regenerative therapies to market, announce the expansion of their existing commercial partnership to bring Kerastem's novel hair growth cell therapy to China and ASEAN Member States....

Read more

Pieris Pharmaceuticals to Present at the 2019 RBC Capital Markets Global Healthcare Conference

May 14, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / May 14, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Allan Reine, Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc. will present at the 2019 RBC Capital Markets Global Healthcare Conference in...

Read more

ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2019

May 13, 2019 3:13 PM

-$0.04/share for the 3 months ended March 31st MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / May 13, 2019 / Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first quarter of 2019 and provided an update on the Company's recent developments. R&D investments of $2.6...

Read more

Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 13, 2019 8:05 AM

Company on track to close acquisition of novel XCART platform technology Entry into CAR T space positions company to drive significant momentum over the course of 2019 advancing XCART platform technology XCART initially being developed to target B-cell lymphomas and has the potential to address multiple tumor types with an initial global market opportunity in Non-Hodgkin Lymphoma of over $5 billion annually 1 FRAMINGHAM,...

Read more

Pieris Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 10, 2019 7:00 AM

Company To Host An Investor Conference Call On Friday, May 10, 2019 At 8:00 AM EDT BOSTON, MA / ACCESSWIRE / May 10, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today reported financial results for the first quarter of 2019 ended March 31, 2019, and provided...

Read more

Dyadic Reports First Quarter 2019 Financial Results and Recent Developments

May 9, 2019 4:00 PM

Trading as DYAI on NASDAQ Capital Market as of April 17New fully-funded proof-of-concept research collaborations with two top twenty-five pharmaceutical companiesSub-licensing agreements with Luina Bio and AlphazymeCollaboration with Serum Institute of India to develop and manufacture up to twelve antibodies and vaccinesExecution of multiple strategic research initiatives further reinforces strength of Dyadic's C1 gene expression platform,...

Read more

INTERIM STATEMENT BY MANAGEMENT - Q1 2019: Positive MAPLE Data for Abicipar, Promising Research Data for Molecular Partners’ Innovative Oncology DARPin(R) Candidates Presented; Recruitment Hold in MP0250 NSCLC trial; Ongoing Focus on Multiple Myeloma for MP0250 Clinical Development

May 9, 2019 1:00 AM

Research & Development: MP0250 (VEGF x HGF) in MM: Additional patient data from ongoing Phase 2 study of MP0250 in combination with Velcade® (PI) support previously observed response rates and duration of treatment MP0250 in combination with osimertinib in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC): Enrollment of new patients on hold due to adverse events; Strategic implications...

Read more

Dyadic and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products and Vaccines

May 8, 2019 9:35 AM

PUNE, INDIA and JUPITER, FL / ACCESSWIRE / May 8, 2019 / Dyadic International, Inc. (''Dyadic'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, is pleased to announce a research and...

Read more

HemaGenetics Announces Completion of the Plan of Arrangement with 1169032 B.C. Ltd.

May 7, 2019 3:20 PM

VANCOUVER, BC / ACCESSWIRE / May 7, 2019 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that further to the previously announced arrangement under the arrangement agreement entered into on June 26, 2018 between the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169029 B.C. Ltd., 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and 1169082 B.C. Ltd. (the "Arrangement"), the Company finalized,...

Read more

Dyadic Announces Sub-Licensing Agreement with Alphazyme

May 6, 2019 4:30 PM

JUPITER, FL / ACCESSWIRE / May 6, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products at flexible commercial scales, is pleased to announce a sub-licensing agreement entered into with...

Read more

Oryzon to Present at Upcoming International Conferences

May 6, 2019 8:00 AM

2019 BioEquity Europe, Barcelona, Spain Chemical Biology Discussion Group Year-End Symposium, New York Academy of Sciences NYC, USA BIO International Convention 2019, Philadelphia, PA, USA Jefferies 2019 Global Healthcare Conference, New York, USA 24th Congress of the European Hematology Association, Amsterdam, The Netherlands MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / May 6, 2019 / Oryzon Genomics, S.A. (ISIN...

Read more